Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption

被引:6
|
作者
MacNealy, Marcus W. C. [1 ]
Newton, Herbert B. [2 ,3 ]
McGregor, John M. [3 ,4 ]
Bell, Susan D. [3 ,5 ]
Chaudhury, Abhik Ray [3 ,6 ]
Slone, H. Wayne [3 ,7 ]
Bourekas, Eric C. [3 ,8 ]
机构
[1] Ohio State Univ, Med Ctr, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Neurol, Columbus, OH 43210 USA
[3] Ohio State Univ, Med Ctr, Richard J Solove Res Inst, Columbus, OH 43210 USA
[4] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Neurol Surg & Radiol, Columbus, OH 43210 USA
[5] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Neurol Surg, Columbus, OH 43210 USA
[6] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Pathol, Columbus, OH 43210 USA
[7] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Radiol, Columbus, OH 43210 USA
[8] Ohio State Univ, Med Ctr, James Canc Hosp, Dept Radiol & Neurol,Sect Diagnost & Int Neurorad, Columbus, OH 43210 USA
关键词
Blood-brain barrier disruption; Dura; Intra-arterial chemotherapy; Leptomeningeal; Lymphoma; Meningeal;
D O I
10.1007/s11060-008-9667-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffuse large B-cell lymphoma of the meninges is a particularly rare form of primary CNS lymphoma. We report a case of a 63-year-old woman found to have primary meningeal lymphoma (PML) with dural and leptomeningeal involvement whom we treated with multiple cycles of intra-arterial (IA) methotrexate, intravenous (IV) etoposide phosphate, and IV cyclophosphamide after reversible osmotic blood-brain barrier disruption (BBBD). Improvement was evident on gadolinium-enhanced brain MRI one month into therapy. At 67 months post-diagnosis there is no evidence of CNS disease. After completing her therapy regimen, she remained disease-free for 34 months, when stage IV diffuse large B-cell lymphoma was discovered in her left adrenal gland and right thigh. Following six cycles of rituximab and CHOP treatment, she is presently in complete remission. IA methotrexate and reversible osmotic BBBD without radiation therapy may be an effective therapy for treating PML.
引用
收藏
页码:329 / 333
页数:5
相关论文
共 50 条
  • [1] Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption
    Marcus W. C. MacNealy
    Herbert B. Newton
    John M. McGregor
    Susan D. Bell
    Abhik Ray Chaudhury
    H. Wayne Slone
    Eric C. Bourekas
    [J]. Journal of Neuro-Oncology, 2008, 90 : 329 - 333
  • [2] Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
    Vicuna-Kojchen, J.
    Frenkel, S.
    Siegal, T.
    Shalom, E.
    Chowers, I.
    Pe'er, J.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (02) : 231 - 235
  • [3] Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors
    Jahnke, K.
    Kraemer, D. F.
    Fortin, D.
    Bell, S.
    Doolittle, N. D.
    Knight, K. R.
    Muldoon, L. L.
    Neuwelt, E. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Enhanced chemotherapy delivery by intra-arterial infusion and blood-brain barrier disruption in cerebral metastasis
    Fortin, David
    Gendron, Cathy
    Boudrias, Marie
    [J]. NEURO-ONCOLOGY, 2006, 8 (04) : 442 - 442
  • [5] Maculopathy Associated With Osmotic Blood-Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma
    Simonett, Joseph M.
    Ambady, Prakash
    Neuwelt, Edward A.
    Skalet, Alison H.
    Lin, Phoebe
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2020, 51 (05): : S5 - S12
  • [6] BLOOD-BRAIN BARRIER DISRUPTION AND INTRA-ARTERIAL METHOTREXATE-BASED THERAPY FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE
    Kobyakov, G. L.
    Aronov, M. S.
    Lubnin, A. Y.
    Yakovlev, S. B.
    Serova, N. K.
    Tropinskaya, O. F.
    Shishkina, L. V.
    Ryzhova, M. V.
    Poddubsky, A. A.
    Inozemtceva, M. V.
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [7] Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
    Angelov, Lilyana
    Doolittle, Nancy D.
    Kraemer, Dale F.
    Siegal, Tali
    Barnett, Gene H.
    Peereboom, David M.
    Stevens, Glen
    McGregor, John
    Jahnke, Kristoph
    Lacy, Cynthia A.
    Hedrick, Nancy A.
    Shalom, Edna
    Ference, Sandra
    Bell, Susan
    Sorenson, Lisa
    Tyson, Rose Marie
    Haluska, Marianne
    Neuwelt, Edward A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3503 - 3509
  • [8] Maculopathy in patients with primary cns lymphoma (PCNSL) treated with osmotic blood-brain barrier disruption (BBBD) in conjunction with chemotherapy
    Vicuna-Kojchen, Joaquin
    Frenkel, Shahar
    Shalom, Edna
    Chowers, Itay
    Pe'Er, Jacob
    Siegal, Tali
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 527 - 527
  • [9] SAFETY OF INTRA-ARTERIAL CHEMOTHERAPY WITH OSMOTIC OPENING OF THE BLOOD-BRAIN BARRIER
    Priest, Ryan
    Ambady, Prakash
    Neweult, Edward
    [J]. NEURO-ONCOLOGY, 2018, 20 : 16 - 16
  • [10] Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors
    Uluc, Kutluay
    Ambady, Prakash
    McIntyre, Matthew K.
    Tabb, John Philip
    Kersch, Cymon N.
    Nerison, Caleb S.
    Huddleston, Amy
    Liu, Jesse J.
    Dogan, Aclan
    Priest, Ryan A.
    Fu, Rongwei
    Netto, Joao Prola
    Siler, Dominic A.
    Muldoon, Leslie L.
    Gahramanov, Seymur
    Neuwelt, Edward A.
    [J]. NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)